Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 1;49(9):e436-e438.
doi: 10.1097/RLU.0000000000005318. Epub 2024 Jun 20.

FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue

Jorge D Oldan, Paula G Landman  1 , Jennifer A Schroeder  2 , Amir H Khandani  2 , Lilja B Solnes  3 , Carrie B Lee  1 , Steven P Rowe
Affiliations
Case Reports

FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue

Jorge D Oldan et al. Clin Nucl Med. .

Abstract

With the increase in use of GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) in the population, nuclear medicine physicians should be aware of the possibility of nondiagnostic FDG PET scans due to these medications, which work partly by increasing insulin secretion. We demonstrate a case where a patient's use of such a medication presumptively led to muscular and myocardial uptake, complicating scan interpretation considerably. Clinicians should be aware of the presence of these drugs and their potential effect on biodistribution in FDG PET. Further study is needed to best understand the effects of these medications on FDG biodistribution.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest and sources of funding: none declared.

References

    1. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA . 2022;327:138–150.
    1. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA . 2021;325:1414–1425.
    1. Wang ZJ, Li XR, Chai SF, et al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology . 2023;240:109716.
    1. Jensen JK, Binderup T, Grandjean CE, et al. Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. Atherosclerosis . 2022;352:88–95.
    1. Cohade C. Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect. Semin Nucl Med . 2010;40:283–293.

Publication types

LinkOut - more resources